Pharmaceutical governance system for costly drugs through human rights due diligence
The obligations and responsibilities of governments and drug companies to increase access to costly new drugs should be grounded in international human rights, write <b>Trudo Lemmens and colleagues</b>
Authors
- Kanksha Mahadevia Ghimire (ORCID: https://orcid.org/0000-0002-0174-3100)
- Ee Ling Low (ORCID: https://orcid.org/0000-0001-5071-1888)
- Katrina Perehudoff (ORCID: https://orcid.org/0000-0003-3958-0244)
- Jillian Clare Köhler (ORCID: https://orcid.org/0000-0003-1290-9484)
- Navindra Persaud (ORCID: https://orcid.org/0000-0003-3327-5580)
- Trudo Lemmens (ORCID: https://orcid.org/0000-0002-9122-0193)
Institutions
- Transparency International (CZ)
- University of Toronto (CA)
- House of Representatives (NL)
- Public Health Ontario (CA)
- University of Amsterdam (NL)
Publication Details
- Journal
- BMJ
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1136/bmj-2023-074982
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.13